Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Icon Bioscience Inc. has received notification from the U.S. FDA that the agency has accepted for filing the company’s recently submitted new drug application (NDA) for DEXYCU® (IBI-10090). DEXYCU reportedly employs Icon’s Verisome® technology to dispense a sustained-release, biodegradable formulation of the anti-inflammatory agent dexamethasone directly into the anterior chamber of the eye through a single injection administered by the physician immediately following cataract surgery.
- Verseon presented preclinical data on multiple novel drug candidates for the treatment of diabetic macular edema (DME) at the 2017 BIO International Conference in San Diego. Verseon is reportedly developing plasma kallikrein inhibitors that target a validated disease pathway and treat an underlying cause of DME.
- pSivida Corp. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market the Company's Durasert three-year treatment for posterior segment uveitis in the European Union (EU).
- Regeneron Pharmaceuticals, Inc. and AbbVie were recently included on The Civic 50 — a recognition granted to the most community-minded companies in the United States by Points of Light, the world's largest organization dedicated to volunteer service.
- And Roche Diagnostics was named as #67 on the list of the country's Best Workplaces for Millennials, announced by research and consulting firm Great Place to Work and FORTUNE.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.